Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05231122
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2022-01-24
Brief Title:
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Sponsor:
Organization:
Roswell Park Cancer Institute